With Shonali Bose’s The Sky Is Pink, Priyanka Chopra Jonas makes her Bollywood comeback after a gap of more than three years. Fans of the actress were eagerly waiting to see her in a Hindi film, and well, the wait has been worth it.
The Sky Is Pink is based on the life of four people, Aisha Chaudhary (Zaira Wasim), Aditi Chaudhary (Priyanka Chopra), Niren Chaudhary (Farhan Akhtar) and Ishaan Chaudhary (Rohit Suresh Saraf). It showcases the struggle that parents go through to save their child and give their child everything that makes her happy.
Well, if you know about the motivational speaker Aisha Chaudhry who was diagnosed with pulmonary fibrosis, and passed away in 2015 at the age of 19, then you might have an idea what the film is going to offer. However, the movie is not just about her or the illness; it is about the Chaudharys who stood with each other in thick and thin.
Shonali Bose has come up with an emotional film that will surely make you cry, but it has scenes that will make you laugh out loud and will also make you go aww… because of the cute moments in it. It’s nowhere overdramatic, and it is very realistic in many ways. It’s a film where you leave the theatre with tears in your eyes and a smile on your face. Yes, that is something very rarely happens.
Talking about performances, Priyanka Chopra Jonas is simply excellent in the film. This is clearly one of the best performances of her career and we won’t be surprised if she takes home the Best Actress trophy at the award functions next year. Zaira Wasim as Aisha is the soul of the film. We really hope that she continues to do movies as it will be a loss for Bollywood if such a talented actress decides to stop acting. Farhan Akhtar is very good in his role and Rohit Suresh Saraf is amazing in the movie.
Overall, The Sky Is Pink is an emotional, heart-warming film with Priyanka Chopra Jonas and Zaira Wasim at their best.
Ratings: 4/5
P.S. Please carry a few tissue papers when you go to watch the film, you will need it.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.